FDA approves olanzapine, a once-monthly subcutaneous injection for adults with schizophrenia, boosting symptom control while reducing monitoring needs and highlighting weight risks.
|Articles|January 1, 2007
Plop, Plop, Fizz, Fizz-and You Can Be a Workout Whiz
When patients cite muscle pain anddiscomfort as an excuse for not exercisingregularly, suggest they try anapproach that athletes use.
Advertisement
When patients cite muscle pain and discomfort as an excuse for not exercising regularly, suggest they try an approach that athletes use. Taking Alka-Seltzer after working out can make muscle-building less painful. Alka-Seltzer contains sodium bicarbonate and aspirin; the sodium bicarbonate alkalinizes the lactic acid produced by the muscles during exertion, and the aspirin helps ease the pain while the kidneys flush the toxins. Do not recommend this use of Alka-Seltzer to patients who are allergic to any of its ingredients, or to those with kidney problems.
- Debra M. Monde, DO
Abilene, Tex
Advertisement
Related to this article
The CardioGuide HF app from Abbott will show patients their pulmonary artery pressure trends and deliver medication instructions set by their care teams.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia
2
9 Drugs Approved for Primary Care: Q3 2026
3
Abbott Gains FDA Approval for CardioMEMS Update Letting Heart Failure Patients View Pressure Readings on Their Phones
4
FDA Clears IDE for NeuWire Medical's STROKE-REWIRE Trial in Chronic Ischemic Stroke
5